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Human pluripotent stem cell (hPSC)-derived endothelial cells and their progenitors are important for vascular research and
therapeutic revascularization. Here, we report a completely defined endothelial progenitor differentiation platform that uses
a minimalistic medium consisting of Dulbecco's modified eagle medium and ascorbic acid, lacking of albumin and growth
factors. Following hPSC treatment with a GSK-3β inhibitor and culture in this medium, this protocol generates more than 30%
multipotent CD34+ CD31+ endothelial progenitors that can be purified to N95% CD34+ cells via magnetic activated cell sorting
(MACS). These CD34+ progenitors are capable of differentiating into endothelial cells in serum-free inductive media. These
hPSC-derived endothelial cells express key endothelial markers including CD31, VE-cadherin, and von Willebrand factor (vWF),
exhibit endothelial-specific phenotypes and functions including tube formation and acetylated low-density lipoprotein
(Ac-LDL) uptake. This fully defined platform should facilitate production of proliferative, xeno-free endothelial progenitor
cells for both research and clinical applications.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Human pluripotent stem cells (hPSCs) are increasingly used in
vascular research, including disease modeling, drug screening,
and development of regenerative therapies (Ashton et al.,⁎ Corresponding author. Fax: +1 608 262 8931.
E-mail address: palecek@engr.wisc.edu (S.P. Palecek).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.scr.2015.05.004
1873-5061/© 2015 The Authors. Published by Elsevier B.V. This is an ope
(http://creativecommons.org/licenses/by-nc-nd/4.0/).2011; Bautch, 2011; Kinney et al., 2014; Kusuma et al., 2014;
Murry and Keller, 2008; Segers and Lee, 2008). Recently,
dramatic improvements in the efficiency of directed differ-
entiation protocols to produce endothelial cells have been
reported by stage-specific modulation of pathways including
TGFβ superfamily (James et al., 2010; Rufaihah et al., 2011;
Wang et al., 2007), VEGF (vascular endothelial growth factor)
(Goldman et al., 2009; James et al., 2010; Rufaihah et
al., 2011; Wang et al., 2007), and Notch signaling (Marcelo etn access article under the CC BY-NC-ND license
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approaches require animal cells, fetal bovine serum, or cyto-
kines and growth factors, limiting their applications for large-
scale endothelial cell production for research or therapeutic
applications.
Recently, we reported a rapid and robust endothelial
progenitor differentiation protocol under serum-free condi-
tions, which only employs a Gsk-3β inhibitor in LaSR
basal medium (Advanced DMEM/F12, 2.5 mM GlutaMAX and
60 μg/mL ascorbic acid) (Lian et al., 2014). The presence of
bovine serum albumin (BSA) in this medium increases the
cost, adds xenogenic components, and heightens lot-to-lot
variability.
Toward developing a defined, xeno-free endothelial
progenitor differentiation platform, we screened several
commercially available basal media, supplemented with
insulin and ascorbic acid, for the ability to generate CD34+
CD31+ cells after treatment with 5 μM CHIR99021. We
found that DMEM supplemented with 100 μg/mL ascorbic
acid generated 20–30% CD34+ CD31+ endothelial progeni-
tors that were enriched to N95% CD34+ progenitors via
MACS. This minimal, defined differentiation platform should
facilitate generation of proliferative endothelial progenitor
cells from hPSCs for both research and clinical applications.
Methods and materials
hPSC culture
hPSCs were maintained in E8 medium on Synthemax ac-
cording to previously published methods (Chen et al., 2011;
Lian et al., 2012, 2013a,2013b).
Endothelial progenitor differentiation via modulation
of canonical Wnt signaling
hPSCs maintained on a Synthemax-coated surface in E8 were
dissociated into single cells with Accutase (Life Technologies)
at 37 °C for 5 min and then seeded onto a Synthemax-coated
cell culture dish at 50,000 cell/cm2 in E8 supplemented with
5 μM ROCK inhibitor Y-27632 (Selleckchem) (day −3) for 24 h.
Cells were then cultured in E8, changed daily. At day 0, cells
were treated with 3–9 μM CHIR99021 (Selleckchem) for
2 days in DMEM (Life Technologies, 11965) supplemented
with 100 μg/mL ascorbic acid (Sigma, A8960) (DMEM/Vc).
After 2 days, CHIR99021-containing medium was aspirated
and cells were maintained in DMEM/Vc without CHIR99021 for
3 to 4 additional days.
Purification and cryopreservation of
endothelial progenitors
Day 5 differentiated populations were dissociated with
Accutase for 10 min and purified with an EasySep Magnet
kit (STEMCELL Technologies) using a CD34 antibody (Miltenyi
Biotec) according to the manufacturer's instructions. After
purification, the total number of enriched CD34+ cells
was counted and the yields were calculated as number of
CD34+ endothelial progenitors generated per hPSC seeded
at day −3. The endothelial progenitor cells were resuspendedat a density of 2 × 106 cells per mL of endothelial freezing
medium, which consists of 30% FBS (Life Technologies), 10%
DMSO (Sigma), 60% EGM-2 (Lonza) and 5 μM Y-27632. 1 mL of
the cell suspension was aliquoted into each cryovial and frozen
in a Mr. FrostyTM freezing container at −80 °C. 24 h later, the
cryovials were transferred to liquid nitrogen for long-term
storage. For recovery, frozen cells were partially thawed in a
37 °C water bath, and were then transferred into a 15-mL
conical tube containing 5 mL 10% FBS DMEM medium (Life
Technologies). After centrifuging, cells were resuspended in
EGM-2 medium (Lonza) or human endothelial-SFM supplement-
ed with 20 ng/mL bFGF and 10 ng/mL EGF (Life Technologies)
containing 5 μM Y27632 and plated into collagen IV-coated
dishes (BD BioCoat) at a density of 0.05 million cells per cm2.
The next day, medium was replaced with fresh room
temperature EGM-2 medium (Lonza) or human endothelial-SFM
supplemented with 20 ng/mL bFGF and 10 ng/mL EGF (Life
Technologies).Differentiation of CD34+ cells to endothelial cells
Day 5 differentiated populations were dissociated with Ac-
cutase for 10 min and purified with an EasySep Magnet kit
(STEMCELL Technologies) using an anti-CD34 antibody ac-
cording to the manufacturer's instructions. The purified
CD34+ cells were plated on collagen IV-coated dishes (BD
BioCoat) in EGM-2 medium (Lonza) or human endothelial-
SFM supplemented with 20 ng/mL bFGF and 10 ng/mL EGF
(Life Technologies) and split every 3–4 days with Accutase.Differentiation of CD34+ cells to smooth
muscle cells
Day 5 differentiated populations were dissociated with
Accutase for 10 min and purified with an EasySep Magnet
kit (STEMCELL Technologies) using an anti-CD34 antibody
according to the manufacturer's instructions. The purified
CD34+ cells were plated on collagen IV-coated dishes (BD
BioCoat) in SmGM-2 medium (Lonza) and split every 3–
4 days with Accutase.Vascular tube formation assay
To assess the formation of capillary structures, 1 × 105 day 15
endothelial cells in 0.4 mL EGM-2 medium (Lonza) supple-
mented with 50 ng/mL VEGF (R&D Systems) were plated into
one well of 24-well tissue culture plate pre-coated with 250 μl
Matrigel (BD Biosciences). Tube formation was observed by
light microscopy after 24 h of incubation.RT-PCR and quantitative RT-PCR
Total RNA was prepared with the RNeasy mini kit (QIAGEN) and
treated with DNase (QIAGEN). 1 μg RNA was reverse tran-
scribed into cDNA via Oligo (dT) with Superscript III Reverse
Transcriptase (Invitrogen). Real-time quantitative PCR was
done in triplicate with iQSYBR Green SuperMix (Bio-Rad).
RT-PCR was performed with Gotaq Master Mix (Promega) and
then subjected to 2% agarose gel electrophoresis. ACTB was
124 X. Bao et al.used as an endogenous housekeeping control. PCR primer
sequences are provided in Supplementary Table 4.
Flow cytometry
Cells were singularized with Accutase for 10 min and then
fixed with 1% paraformaldehyde for 20 min at room temper-
ature and stained with primary and secondary antibodies
(Supplemental Table 3) in PBS plus 0.1% Triton X-100 and 0.5%
BSA. Data were collected on a FACSCaliber flow cytometer
(Beckton Dickinson) and analyzed using FlowJo. For ICAM-1
expression, day 15 post-purified endothelial cells were treated
with or without 10 ng/mL TNFα for 16 h prior to flow
cytometry analysis.
Immunostaining
Cells were fixed with 4% paraformaldehyde for 15 min at
room temperature and then stained with primary and
secondary antibodies (Supplemental Table 3) in PBS plus
0.4% Triton X-100 and 5% non-fat dry milk (Bio-Rad). Nuclei
were stained with Gold Anti-fade Reagent with DAPI
(Invitrogen). An epifluorescence microscope (Leica DM IRB)
with a QImaging® Retiga 4000R camera was used for imaging
analysis.
Results
Albumin-free medium for endothelial
progenitor differentiation
We previously demonstrated that activation of canonical
Wnt signaling in hPSCs in LaSR basal medium generates
functional CD34+/CD31+ endothelial progenitors in numer-
ous hPSC lines (Lian et al., 2014). Figs. 1A and S1 show
schematics of the endothelial differentiation and purifica-
tion protocols. LaSR basal medium consists of advanced
DMEM/F12 medium, which contains proteins including
transferrin and BSA (AlbuMAX II) (Supplementary Table 1).
To develop a defined, xeno-free medium for endothelial
progenitor differentiation, we assessed the efficiency of
endothelial progenitor differentiation induced in H13 human
embryonic stem cells (hESCs) by 6 μM CHIR99021 treatment
in 4 commercially available basal media supplemented with
10 μg/mL insulin and 60 μg/mL ascorbic acid, as these two
factors were shown to enhance endothelial cell proliferation
and differentiation (May and Harrison, 2013; Montecinos et
al., 2007; Piecewicz et al., 2012; Zhao et al., 2011). Only
DMEM generated more than 10% CD34+ CD31+ endothelial
progenitors. Supplementing DMEM with ascorbic acid signif-
icantly increased the percentage of endothelial progenitors
at day 5, while insulin diminished endothelial progenitor
purity. Other basal media yielded few, if any, CD34+ CD31+
cells (Fig. 1B).
We optimized the concentrations of CHIR99021 (CH)
and ascorbic acid in DMEM and found that 5 μM CH and
100 μg/mL ascorbic acid provided the greatest purity of
endothelial progenitors (Fig. 1C, D). Next, we tested DMEM
supplemented with ascorbic acid as an endothelial progenitor
differentiation medium in multiple additional hESC (H1, H14)and iPSC (19-9-11, 6-9-9, 19-9-7) lines at passages between 20
and 100, and they all generated 20–30% CD34+ CD31+ cells
(Fig. S2, Supplementary Table 2), comparable to the differ-
entiation efficiencies reported in LaSR basal medium (Lian et
al., 2014).CD34+ CD31+ endothelial progenitors
are multipotent
Molecular analysis during endothelial progenitor differenti-
ation showed dynamic changes in gene expression, with
downregulation of the pluripotency markers NANOG, SOX2,
and OCT4, and induction of mesoderm genes T, MIXL1 and
EOMES in the first 24 h after CHIR99021 addition (Fig. 2A).
Expression of the endothelial progenitor markers KDR, CD34,
CDH5 and CD31 was detected at day 4 and increased at day
5 (Fig. 2A). Immunofluorescent analysis revealed robust
surface expression of both CD34 and CD31 on day 5 (Fig. 2B).
In addition, flow cytometry profiling during endothelial
progenitor differentiation showed a population of cells
expressing CD144, but not ICAM-1, appeared at day 5 (Fig.
S3A), consistent with our previous report of hPSC differen-
tiation to endothelial progenitors in albumin-containing
medium (Lian et al., 2014). To further investigate the
multipotent nature of these CD34+/CD31+ cells, single step
MACS using an anti-CD34 antibody was performed on day 5 of
differentiation, yielding 99% pure CD34+ cells (Fig. 2C).
Additional cell lines were also enriched to N95% CD34+
populations with a yield of 4–5 CD34+ endothelial progen-
itors for every input hPSC (Fig. S2, Supplementary Table 2).
The purified CD34+ cells were plated on Collagen IV-coated
96-well plates at a density of one cell per well in either
endothelial or smooth muscle medium. After 10 days of
culture, they generated relatively pure populations of cells
expressing smooth muscle myosin heavy chain (SMMHC),
smooth muscle actin (SMA) and calponin, or VE-cadherin,
vWF and CD31, respectively (Fig. 2D and E), indicating their
multipotency. In addition, we tested whether day 5 CD34+
cells exhibit hematopoietic potential in IMDM medium
supplemented with growth factor cocktails (300 ng/mL
stem cell factor (SCF), 300 ng/mL Flt-3, 50 ng/mL colony-
stimulating factor 3 (CSF3), 10 ng/mL IL-3, and 10 ng/mL
IL-6) shown to sustain human hematopoietic stem cells
(Wang et al., 2004), but did not detect CD45+ cells after
7 days (Fig S3B).Characterization of hPSC-derived endothelial cells
To further assess the intrinsic properties of endothelial cells
differentiated from CD34+ cells generated in this defined
platform, MACS-sorted CD34+ cells were cultured in com-
mercial endothelial media (EGM2 and human endothelial
SFM) on collagen IV-coated plates. The resulting cells
exhibited morphological characteristics typical of primary
endothelial cells (Fig. S1). These hPSC-derived endothelial
cells proliferated actively and were capable of 20 population
doublings over 2 months in serum-containing EGM2 (Fig. 3A).
Flow cytometry and immunostaining analysis of cells dif-
ferentiated in serum-free human endothelial SFM revealed
robust expression of CD31, VE-cadherin and vWF, comparable
Figure 1 Defined, xeno-free medium for hPSC differentiation to CD34+ CD31+ endothelial progenitors via Gsk-3β inhibitor
treatment. (A) Schematic of the protocol for defined, xeno-free differentiation of hPSCs to endothelial progenitors in a single
albumin-free differentiation medium. (B) H13 hESCs were cultured as indicated in (A) in different differentiation media and the
percentage of CD34+ CD31+ cells was determined by flow cytometry. (C) H13 hESCs were cultured on Synthemax in DMEM containing
60 μg/mL ascorbic acid and the indicated concentrations of CH for 2 days followed by another 3 days in the same medium and the
percentage of CD34+ CD31+ cells was determined by flow cytometry. (D) H13 hESCs were cultured on Synthemax and treated with
5 μM CH for 2 days followed by another 3 days in DMEM medium supplemented with indicated concentration of ascorbic acid and the
percentage of CD34+ CD31+ cells was determined by flow cytometry. All analyses of CD34 and CD31 expression were performed after
5 days of differentiation. Data are represented as mean ± s.e.m. of at least three independent replicates.
125Differentiation of human pluripotent stem cells to endothelial progenitor cellsto primary human umbilical vein endothelial cells (HUVECs)
(Fig. 3B, C).
Next, we assessed the endothelial nature of these hPSC-
derived CD31+ cells differentiated in serum-free media
by testing for tube formation and acetylated low-density
lipoprotein (Ac-LDL) uptake. Upon treatment with VEGF, the
cells organized into tube-like structures in Matrigel (Fig. 3D),
and were able to take up Ac-LDL (Fig. 3E), demonstratingtheir endothelial function. In addition, these hPSC-derived
endothelial cells upregulated expression of the adhesion
molecule ICAM-1 upon TNF-α treatment (Fig. S3C), indicat-
ing their ability to respond to inflammatory mediators.
Furthermore, they also maintained viability (Fig. S4A)
and endothelial marker expression after storage in liquid
nitrogen for a month (Fig. S4B, C), indicative of cryopreser-
vation ability.
Figure 2 Molecular analysis of endothelial progenitors differentiated from hPSCs. (A-B) H13 hESCs were differentiated as
illustrated in Fig. 1A using DMEM medium supplemented with 100 μg/mL ascorbic acid. At different time points, developmental gene
expression was assessed by quantitative RT-PCR (A). Color key is in log10 scale. Day 5 cells were subjected to immunostaining analysis
for CD34 and CD31 (B). (C-E) At day 5, CD34+ cells were enriched with the EasySep™ Human CD34 Positive Selection Kit and
purification quantified by flow cytometry for CD34 expression (C). Sorted CD34+ cells were plated in (D) smooth muscle medium or (E)
EGM2 endothelial cell medium at a density of one cell per well of 48-well plate and cultured for another 10 days. Sample
immunofluorescence images for smooth muscle and endothelial markers were shown. Scale bars, 50 μm.
126 X. Bao et al.Discussion
Existing methods for hPSC differentiation to endothelial
progenitors require the addition of growth factors and/or
xenogenic components, limiting their application for large-
scale production and therapeutic applications (Bautch, 2011;Wilson et al., 2014). Here, we report a defined, albumin-free,
non-xenogenic differentiation system for directing hPSCs to
endothelial progenitors. We showed that a completely defined
medium, DMEM supplemented with 100 μg/mL ascorbic acid,
is sufficient to efficiently generate CD34+ CD31+ endothelial
progenitors from hPSCs following Gsk-3β inhibition. These
Figure 3 Characterization of endothelial cells differentiated from hPSCs. (A) H13 hESCs were differentiated as illustrated in Fig. 1A
using DMEM/Vc medium. At day 5, CD34+ cells were enriched and cultured in endothelial medium on collagen IV-coated plates.
(A) Cells cultured in EGM2 were passaged every five days. At different time points, the cell numbers were counted and the number of
cumulative population doublings was calculated. Data are represented as mean ± standard deviation of three independent
replicates. (B-E) CD34+ cells were cultured in serum-free human endothelial SFM. The purified day 15 endothelial cells were
immunostained for CD31 (B), VE-cad and vWF (C), and tested for (D) tube-forming ability upon VEGF treatment and the ability to (E)
uptake Ac-LDL. Data are represented as mean ± s.e.m. of at least three independent replicates. Scale bars, 50 μm.
127Differentiation of human pluripotent stem cells to endothelial progenitor cellshPSC-derived endothelial progenitors are multipotent and can
be further directed into smooth muscle cells or endothelial
cells upon subsequent culture in appropriate inductive media.CD31+/VE-cadherin+ endothelial cells differentiated under
serum-free conditions exhibited uptake of acetylated low-
density lipoprotein (Ac-LDL) and formed tube-like structures
128 X. Bao et al.when cultured on Matrigel in the presence of VEGF. However,
long-term expansion of these cells required serum-containing
medium.
Albumin has been reported to increase growth rate and
overall cell health (Ashman et al., 2005; Zoellner et al.,
1996). Here, however, we demonstrate that albumin is
dispensable in endothelial progenitor differentiation. In spite
of the greater simplicity of this new albumin free-medium, it
supported endothelial progenitor induction of hPSCs compara-
bly to LaSR basal medium. This simplified medium offers
several advantages in both research and clinical applications
of hPSC-derived endothelial progenitors. First, it eliminates
batch-to-batch variability of albumin, likely increasing repro-
ducibility of differentiation processes. Second, it provides a
simpler chemical background for examining and screening
factors regulating gene expression, differentiation, and prolif-
eration. For example, albumin can bind and sequester lipids,
proteins and small molecules (Garcia-Gonzalo and Izpisúa
Belmonte, 2008). Third, it can reduce the risk of potential
pathogen contamination and cell immunogenicity, facilitating
therapeutic applications of hPSC-derived endothelial progen-
itor cells. Finally, this new system can significantly reduce
reagent cost and simplify quality control for endothelial
progenitor cell differentiation.
Conclusions
This study demonstrates that a completely defined, xeno-
free medium can be used to efficiently derive functional
endothelial progenitors from hPSCs in the absence of
exogenous proteins. This is an important step toward the
ultimate clinical application of hPSC-derived endothelial
progenitors.
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